News

On March 10, 2026, the first production batch of the ARRIAH-IBD “Medius” vaccine, developed by the FGBI "ARRIAH" researchers, was placed on the market in the amount of 25 million doses. This allows its sale throughout the territory of Russia and EAEU member countries.

The VMP is the first vaccine for the prevention of infectious bursal disease (Gumboro disease) in chicks, developed as part of the comprehensive scientific and technical project of the "Development of technologies for production of veterinary medicinal products" subprogram of the Federal Scientific and Technical Program for Agricultural Development for 2017-2030.

The vaccine contains an attenuated strain of IBD virus, providing an optimal balance between safety and effectiveness. It forms persistent immunity, is capable of overcoming strong transovarial (maternal) immunity, and does not have a negative effect on the immune system organs, including the bursa — the key organ responsible for immunity formation in young chickens. Previously, there were no vaccines based on this strain on the domestic market.

The placement of the vaccine on the market has become an important step in implementing the import substitution strategy and will allow poultry establishments to use a domestic VMP based on current strains to ensure animal disease freedom in the country.